Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
- PMID: 17242417
- DOI: 10.1194/jlr.C600025-JLR200
Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice
Abstract
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a member of a family of proteases that is thought to promote the degradation of the low density lipoprotein receptor (LDLR) through an as yet undefined mechanism. We developed second generation antisense oligonucleotide (ASO) inhibitors targeting murine PCSK9 to determine their potential as lipid-lowering agents. Administration of a PCSK9 ASO to high fat-fed mice for 6 weeks reduced total cholesterol and LDL by 53% and 38%, respectively. Moreover, inhibition of PCSK9 expression resulted in a 2-fold increase in hepatic LDLR protein levels. This phenotype closely resembles that reported previously in Pcsk9-deficient mice. The absence of cholesterol lowering in Ldlr-deficient mice effectively demonstrated a critical role for this receptor in mediating the lipid-lowering effects of PCSK9 inhibition. Antisense inhibition of PCSK9 is an attractive and novel therapeutic approach for treating hypercholesterolemia in human.
Similar articles
-
A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo.PLoS One. 2010 May 17;5(5):e10682. doi: 10.1371/journal.pone.0010682. PLoS One. 2010. PMID: 20498851 Free PMC article.
-
Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis.J Am Coll Cardiol. 2013 Oct 15;62(16):1401-8. doi: 10.1016/j.jacc.2013.07.056. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23973703 Review.
-
Serum proprotein convertase subtilisin/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation.Circulation. 2013 Jun 18;127(24):2403-13. doi: 10.1161/CIRCULATIONAHA.113.001592. Epub 2013 May 20. Circulation. 2013. PMID: 23690465 Free PMC article.
-
Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?J Cardiovasc Pharmacol Ther. 2015 Mar;20(2):157-68. doi: 10.1177/1074248414539562. Epub 2014 Jun 17. J Cardiovasc Pharmacol Ther. 2015. PMID: 24938457 Review.
-
The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.Pharmacol Res. 2013 Jul;73:27-34. doi: 10.1016/j.phrs.2013.04.001. Epub 2013 Apr 8. Pharmacol Res. 2013. PMID: 23578522 Review.
Cited by
-
PCSK9 LNA antisense oligonucleotides induce sustained reduction of LDL cholesterol in nonhuman primates.Mol Ther. 2012 Feb;20(2):376-81. doi: 10.1038/mt.2011.260. Epub 2011 Nov 22. Mol Ther. 2012. PMID: 22108858 Free PMC article.
-
The PCSK9 decade.J Lipid Res. 2012 Dec;53(12):2515-24. doi: 10.1194/jlr.R026658. Epub 2012 Jul 17. J Lipid Res. 2012. PMID: 22811413 Free PMC article. Review.
-
Antitumor activity and molecular mechanism of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition.Naunyn Schmiedebergs Arch Pharmacol. 2022 Jun;395(6):643-658. doi: 10.1007/s00210-022-02200-y. Epub 2022 Mar 21. Naunyn Schmiedebergs Arch Pharmacol. 2022. PMID: 35307759 Review.
-
PCSK9 in Liver Cancers at the Crossroads between Lipid Metabolism and Immunity.Cells. 2022 Dec 19;11(24):4132. doi: 10.3390/cells11244132. Cells. 2022. PMID: 36552895 Free PMC article. Review.
-
Proprotein convertases in high-density lipoprotein metabolism.Biomark Res. 2013 Sep 18;1(1):27. doi: 10.1186/2050-7771-1-27. Biomark Res. 2013. PMID: 24252756 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Miscellaneous